CD8A and neoplasm: There was a significant increase in T cells (CD3+ and CD8+) in both the tumor (CD3+, p = 0,009; adj p = 0.036, CD8 + , p = 0.04; adj p = 0.04) and stromal regions (CD3+, p = 0.001; adj p = 0.004, CD8 + , p = 0.009; adj p = 0.018) within the TME after treatment with cryo-tremelimumab combination therapy.